North Growth Management Ltd. Zymeworks Inc. Transaction History

North Growth Management Ltd.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 18, 2022	BUY	$4.82 - $7.7 $361,500 - $577,500	75,000 New	75,000 $399,000
Q1 2022 Apr 14, 2022	SELL	$6.0 - $16.98 $414,000 - $1.17 Million	-69,000 Closed	0 $0
Q4 2021 Feb 07, 2022	BUY	$15.19 - $29.33 $91,140 - $175,980	6,000 Added 9.52%	69,000 $1.14 Million
Q3 2021 Oct 14, 2021	BUY	$27.35 - $37.28 $136,750 - $186,400	5,000 Added 8.62%	63,000 $1.83 Million
Q1 2021 May 07, 2021	BUY	$29.83 - $56.81 $268,470 - $511,290	9,000 Added 18.37%	58,000 $1.84 Million
Q3 2019 Nov 14, 2019	BUY	$22.78 - $29.08 $1.12 Million - $1.42 Million	49,000 New	49,000 $1.22 Million

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $903M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of North Growth Management Ltd., based on Form 13F filings with the SEC.

Stay updated on North Growth Management Ltd. with notifications on news.